CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. | The deal allows CSL to ...
Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
The FDA has flagged J&J Medtech’s recall of its Cerepak detachable coils as Class I in the wake of one death and four serious injuries. | The FDA has flagged J&J Medtech’s recall of Cerepak detachable ...
Bristol Myers Squibb is partnering up with Evinova’s AI clinical development platform across the Big Pharma company’s global portfolio in an effort to improve efficiency and cut costs.
After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has inked a multi-year deal to access Iambic Therapeutics' broad suite of | ...
When Expertise, Monitoring, Systems, and AI AlignBy Amir Malka, CEO, Bioforum The Data Masters | Trial oversight is shifting ...
Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to ...
AI is no longer a future concept in life sciences — it is actively reshaping how clinical trials are designed, executed and ...
Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this ...
Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...
Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results